IL-2 Binding Antibodies Modulate Receptor Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for conditions associated with IL-2 signaling, such as cancer, face challenges in effectively modulating IL-2 signaling to enhance clinical and immune responses.
Innovation Solution
Development of antibodies that specifically bind to human IL-2 with high affinity, differentially affecting IL-2 binding to IL-2 receptor chains, thereby modulating IL-2 signaling. These antibodies inhibit IL-2 signaling through various receptor combinations, particularly targeting IL-2 Rαβγ and IL-2 Rβγ, with some variants showing significant inhibition of IL-2 Rαβγ signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional IL-2 therapies are used to treat cancer, then immune response is enhanced, but side effects and limited clinical efficacy occur
Solution Approach 1:
The antibody differentially modulates IL-2 binding to different receptor chains (IL-2Rα, IL-2Rβ, IL-2Rγ) with varying affinities, creating localized selective inhibition. This allows preferential suppression of certain immune cell populations (like Tregs expressing high IL-2Rα) while preserving or enhancing responses in other cells, thereby improving therapeutic efficacy while reducing non-specific side effects
Solution Approach 2:
The invention changes the binding parameters of IL-2 by introducing an antibody that alters the affinity and stoichiometry of IL-2-receptor interactions. The antibody-IL-2 complex creates modified binding characteristics that shift the equilibrium of receptor occupancy, enabling selective modulation of signaling pathways to achieve better therapeutic outcomes with reduced toxicity
2Reliability
If IL-2 signaling is strongly inhibited to reduce side effects, then therapeutic index improves, but immune response enhancement is reduced
Solution Approach 1:
The antibody creates differential inhibition across different IL-2 receptor expressing cell types. By targeting specific receptor chain combinations with different binding affinities, it selectively suppresses overactive or harmful immune responses while preserving or enhancing protective immune responses, thereby improving the therapeutic index without broadly dampening immune function
Solution Approach 2:
The antibody provides partial inhibition of IL-2 signaling rather than complete blockade. This partial action allows sufficient immune activation to occur while preventing excessive signaling that leads to side effects, achieving an optimal balance between therapeutic benefit and toxicity reduction
Data Source
AI summary
The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.